Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer

Abiraterone acetate is the first second-line hormonal agent proven to improve survival in metastatic castration-resistant prostate cancer. It selectively inhibits cytochrome P450 17 (CYP17) α-hydroxylase and cytochrome(17,20) (C(17,20))-lyase, which are enzymes critical for androgen synthesis. Abira...

Descripción completa

Detalles Bibliográficos
Autores principales: Harshman, Lauren C., Taplin, Mary-Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778906/
https://www.ncbi.nlm.nih.gov/pubmed/23979793
http://dx.doi.org/10.1007/s12325-013-0050-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778906/
https://www.ncbi.nlm.nih.gov/pubmed/23979793
http://dx.doi.org/10.1007/s12325-013-0050-3

Ejemplares similares